Castle Creek Biosciences Revenue and Competitors

Location

$196.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Castle Creek Biosciences's estimated annual revenue is currently $3.5M per year.(i)
  • Castle Creek Biosciences's estimated revenue per employee is $77,500
  • Castle Creek Biosciences's total funding is $196.6M.

Employee Data

  • Castle Creek Biosciences has 45 Employees.(i)
  • Castle Creek Biosciences grew their employee count by -18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$3.3M21-5%N/AN/A
#3
$1.4M90%N/AN/A
#4
$2.3M1525%N/AN/A
#5
$10.5M681%N/AN/A
#6
$0.7M717%N/AN/A
#7
$4.8M31-11%N/AN/A
#8
$1.6M929%N/AN/A
#9
$7.4M48-11%N/AN/A
#10
$1.9M12-25%N/AN/A
Add Company

Castle Creek Biosciences, Inc. is a privately-held, clinical-stage cell and gene therapy company advancing innovative personalized therapies for underserved disorders with high unmet medical needs.

keywords:N/A

$196.6M

Total Funding

45

Number of Employees

$3.5M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Castle Creek Biosciences's People

NameTitleEmail/Phone
1
AVP Process Sciences
2
Director Quality Technology
3
SVP, Commercial
4
Associate VP, Clin Ops
5
Information Technology Support Administrator
6
VP Human Resources
7
Quality Assurance / Validation
8
Executive Assistant to President & CEO
9
Principal Scientist
10
VP Manufacturing

Castle Creek Biosciences News

2022-04-20 - Worldwide Adoptive Cell Therapy Industry to 2030 - Featuring ...

Novartis AG. Gilead Sciences, Inc. Castle Creek Biosciences, Inc; Lineage Cell Therapeutics, Inc. Transgene SA; Cellectis; ImmunityBio, Inc...

2022-04-06 - Dystrophic Epidermolysis Bullosa Treatment Market Report ...

... Treatment Market Report Covers Future Trends With Research 2022 to 2029 – Krystal Biotech, Castle Creek Biosciences, Abeona Therapeutics.

2022-03-30 - Evozyne Announces Multi-Target Research Collaboration and ...

... founded by Paragon Biosciences, announced today that it has ... The company's current portfolio includes Castle Creek Biosciences,...

2021-09-29 - Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

EXTON, Pa., Sept. 29, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, toda ...

2020-03-25 - Castle Creek Biosciences Raises $75M in Funding

Castle Creek Biosciences, Inc., an Exton, Pa.-based late-stage gene therapy company, received $75m in equity and debt funding. Paragon Biosciences led the $55m equity investment with participation from Fidelity Management & Research Company and Valor Equity Partners. A $20m venture loan was pro ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.9M45-10%N/A
#2
$4.4M4653%N/A
#3
$5.6M4712%N/A
#4
$3.5M477%N/A
#5
$13.8M499%N/A